Related Experiment Video
Updated: Aug 18, 2025
Author Spotlight: Understanding the Mechanism of Tuina Manipulation in Rats
Published on: June 30, 2023
Inhibition of transforming growth factor-β in osteoarthritis. Discrepancy with reduced TGFβ signaling in normal
1Radboud University Medical Center, Experimental Rheumatology, Interdisciplinary Consortium for Clinical Movement Sciences and Technology. PO Box 9101, 6500HB, Nijmegen, the Netherlands.
Objective:
Transforming growth factor-β (TGFβ) is a pleiotropic cytokine that is central in the regulation of joint health and disease. Inhibition of TGFβ activity/signaling in experimental osteoarthritis (OA) has been performed to modulate OA severity and progression. In this narrative review we discuss the potential reasons for the variable results of TGFβ inhibition in these models.
Design:
A literature study was performed using the search terms; experimental osteoarthritis and TGFβ. Papers were selected that describe the effect TGFβ activity/signaling inhibition on experimental OA. Based on the selected papers a narrative review has been written about the potential therapeutic role of TGFβ inhibition in OA and potential causes for its variable effects are discussed.
Results:
Inhibition of TGFβ activity in experimental models of OA does not result in either straightforward protection or deleterious effects. More than half of the studies (13/19), but not all, report that inhibition of TGFβ in experimental OA reduces OA severity. This is in contrast with the protective role of TGFβ in healthy joints.
Conclusions:
The effect of TGFβ inhibition on joint damage in experimental OA is variable. Most likely this is a consequence of the changing function of TGFβ in normal and OA joints. As a result, the overall outcome of TGFβ modulation in OA will be unpredictable. To develop OA therapies based on modulation of TGFβ activity specific protective and damaging signaling routes should be identified and tools developed to block the damaging ones.
Insights
Transforming growth factor-β (TGFβ) inhibition in experimental osteoarthritis (OA) shows variable effects on joint damage. Identifying specific signaling pathways is crucial for developing targeted OA therapies.
Area of Science:
- Rheumatology and Joint Disease Research
- Molecular Signaling in Pathogenesis
Background:
- Transforming growth factor-β (TGFβ) is a key cytokine regulating joint homeostasis and disease.
- TGFβ signaling plays a complex role in both maintaining healthy joints and driving osteoarthritis (OA) pathogenesis.
Purpose of the Study:
- To review the variable outcomes of inhibiting TGFβ activity in experimental OA models.
- To explore the reasons behind the inconsistent effects of TGFβ inhibition on OA severity.
Main Methods:
- A narrative review of existing literature was conducted.
- Search terms included "experimental osteoarthritis" and "TGFβ".
- Papers detailing TGFβ inhibition effects in experimental OA were selected and analyzed.
Main Results:
- Inhibition of TGFβ in experimental OA yielded inconsistent results, with no clear protective or detrimental effect.
- A majority of studies (13/19) reported reduced OA severity upon TGFβ inhibition.
- These findings contrast with the known protective role of TGFβ in healthy joint maintenance.
Conclusions:
- The variable effects of TGFβ inhibition in OA are likely due to its changing functions in healthy versus diseased joints.
- Predicting the overall outcome of TGFβ modulation in OA is challenging.
- Future OA therapies targeting TGFβ require identification of specific protective and damaging signaling pathways.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
11:38Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
Related Concept Videos
01:16TGF - β Signaling Pathway
01:20The JAK-STAT Signaling Pathway